Angiochem Is A Clinical Stage Biotechnology Company Based In Montrealcanadafounded In 2003The Company Specializes In Developing Therapeutics For The Central Nervous Systemcns Focusing On Overcoming The Blood Brain Barrierbbbusing Its Proprietary Engineered Peptide Compoundsepicplatformthis Innovative Approach Utilizes The Lrp 1 Receptor Mediated Pathway To Deliver Drugs Directly Into The Brain The Company Is Advancing A Pipeline Of Peptide Drug Conjugates And Biologics Aimed At Treating Challenging Neurological Disordersincluding Brain Cancers Like Glioblastomaneurodegenerative Diseaseslysosomal Storage Disordersand Chronic Painone Of Its Notable Candidatesang1005Has Demonstrated Clinical Benefits In Treating Brain Metastases And Leptomeningeal Carcinomatosis During Phase Ii Trialsangiochem Holds 35 Filed Patentsshowcasing Its Commitment To Developing Effective Treatments For Both Common And Rare Neurological Conditions
